VivoSeq
Other

Osimertinib

0

Pipeline Programs↗

14

Active Trials↗

3

Companies Involved↗

Osimertinib is an early-stage landscape with 0 programs across 3 companies. The most active players are AstraZeneca, Boehringer Ingelheim, Ascentage Pharma Group Inc..

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

89/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalAscentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

25

clinical trials

Completed8 · 32%
Active, not recruiting5 · 20%
Not yet recruiting5 · 20%
Recruiting4 · 16%
Unknown status2 · 8%
Terminated1 · 4%

Clinical Trials

Trial Activity

25 trials

Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients
Recruiting·IInstituto Oncológico Dr Rosell·Phase 1·NCT04772235·32 enrolled
A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
Recruiting·SShanghai Chest Hospital·Phase 2·NCT07058519·250 enrolled
Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05686434·65 enrolled
A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
Recruiting·SSuzhou Genhouse Bio Co., Ltd.·Phase 1/2·NCT06306456·94 enrolled
Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC
Active, not recruiting·GGuangdong Association of Clinical Trials·Phase 2·NCT05163249·44 enrolled
Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)
Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT02856893·156 enrolled
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
Active, not recruiting·Ascentage Pharma Group Inc. logoAscentage Pharma Group Inc.·Phase 1·NCT04001777·80 enrolled
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
Active, not recruiting·AstraZeneca logoAstraZeneca·Phase 2·NCT03778229·367 enrolled
Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
Active, not recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT03667820·41 enrolled
Boosting Osimertinib Blood Brain Barrier Penetration
Not yet recruiting·MMaastricht University Medical Center·Phase 2·NCT07485452·7 enrolled
Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients
Not yet recruiting·GGruppo Oncologico Italiano di Ricerca Clinica·N/A·NCT07363252·100 enrolled
Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer
Not yet recruiting·—·Phase 1·NCT06067776·36 enrolled
The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC
Not yet recruiting·—·N/A·NCT06117644·30 enrolled
Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib
Not yet recruiting·SShanxi Province Cancer Hospital·Phase 1/2·NCT07486648·53 enrolled
Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation
Completed·SSeoul National University Hospital·Phase 2·NCT03414814·15 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)